Cardiovascular Revascularization Medicine
Volume 10, Issue 2 , Pages 130-135 , April 2009

Recurrent very late drug-eluting stent thrombosis

Received 21 June 2008 ,Accepted 23 June 2008.

References 

  1. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667–678
  2. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug eluting stents. JAMA. 2005;293:2126–2130
  3. Ong ATL, McFadden EP, Regar E, De Jaegere PPT, Van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug eluting stents. J Am Coll Cardiol. 2005;45:2088–2092
  4. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fisha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST study. J Am Coll Cardiol. 2005;46:1827–1832
  5. Price J, Wong G, Valenica R, Lee S, Gollapudi R, Teirstein P. Measurement of clopidogrel inhibition with a point-of-care assay identifies patients at risk for stent thrombosis after percutaneous coronary intervention. Am J Cardiol. 2006;98(Suppl):204M
  6. Pramod K, Kuchulakanti , Chu WW, Torguson R, et al. Correlates and Long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–1113
  7. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159–168
  8. Melikian N, Wjins W. Drug eluting stents: a critique. Heart. 2008;94(2):145–152
  9. Mauri L, Hsieh WH, Massaro JM, Ho KK, D'Agostino R, Cutlip DE. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020–1029
  10. Moreno R, Fernandez C, Hernandez R, et al. Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized trials. J Am Coll Cardiol. 2005;45:954–959
  11. Faxon DP. Debate: should drug-eluting stent use be curtailed in the milieu of mounting safety concerns?. In: Transchateter Cardiovascular Therapeutics Annual Meeting 2006, Washington DC. 2006;
  12. de la Torre-Hernàndez JM, Alfonso F, Hernàndez F, et al. Drug-Eluting Stent Thrombosis: Results From the Multicenter Spanish Registry ESTROFA (Estudio ESpañol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol. 2008;51:986–990
  13. Hoffmann R, Morice M-C, Moses JW, Fitzgerald PJ, Mauri L, Breithardt L, et al. Impact of late incomplete stent apposition after sirolimus-eluting stent implantation on 4-year clinical events: intravascular ultrasound analysis from the multicentre, randomised, RAVEL, E-SIRIUS and SIRIUS trials. Heart. 2008;94:322–328
  14. Joner M, Finn AV, Farb A, et al. Pathology of drug eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202
  15. Colombo A, Latib A. Late incomplete stent apposition after drug-eluting stent implantation: a true risk factor or an innocent bystander?. Heart. 2008;94:253–254
  16. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation. 2006;113:414–419
  17. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation. 2007;115:2426–2434

PII: S1553-8389(08)00245-5

doi: 10.1016/j.carrev.2008.06.005

Cardiovascular Revascularization Medicine
Volume 10, Issue 2 , Pages 130-135 , April 2009

Article Tools

* Image Usage & Resolution